STAT+ revisited Huidagene’s gene editing trial decisions after a child’s death, with gene-editing experts dissecting how early trial data and presentation choices may have influenced risk assumptions. The analysis centers on actions by former CEO Alvin Luk, who reportedly presented early data three months before the death at a major AGCT Presidential Symposium. Experts interviewed by STAT+ offered sharply divided views on the quality of the science and the appropriateness of the approach. The episode adds to ongoing concerns about oversight, transparency, and trial design in cross-border gene editing efforts. For biotech leaders, the case underscores how quickly reputational and regulatory consequences can emerge when safety signals or interpretability gaps surface—particularly in trials operating under opaque enrollment and reporting conditions.